BioHarvest lands $1.4M grant for AI-driven plant science
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Wednesday it has received a 4.33 million NIS (about $1.4 million) grant from the Israel Innovation Authority to fund a new research initiative applying machine learning and computer vision to its plant cell culture programs. The non-dilutive funding, BioHarvest's second grant from the IIA this year, will support integration of data science, chemo-informatics and high-throughput digital sensing into the company's biological development workflows, aiming to move plant cell culture away from trial-and-error methods toward a data-driven optimization framework.
BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript
BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript
BioHarvest Sciences Q1 Earnings Call Highlights
BioHarvest Sciences NASDAQ: BHST reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, platform.
BioHarvest Sciences Q1 revenue climbs as it expands botanical synthesis pipeline
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported an 8% jump in first quarter revenue as the company advanced several contract development and manufacturing organization (CDMO) projects and expanded its direct-to-consumer wellness business. The company posted first quarter revenue of $8.5 million, up from $7.9 million a year earlier, while maintaining its full-year revenue guidance range of $42 million to $48 million.
BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Beats Revenue Estimates
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
BioHarvest Sciences advances synthetic saffron program with SaffronTech partnership
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said that it has completed the first stage of a multi-stage development agreement with SaffronTech, establishing a stable saffron cell bank that the company says could one day offer a sustainable alternative to one of the world's most expensive agricultural commodities. The Nasdaq-listed biotech said completion of Stage 1 has triggered the start of Stage 2 under the ongoing agreement, which will focus on using its patented Botanical Synthesis platform to generate enough biomass to support pre-commercial testing and product development for nutraceutical and culinary applications.
BioHarvest Sciences wins $1.2M fragrance contract
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) has secured a $1.2 million Stage 2 contract to develop a rare scent-producing plant compound for the global fragrance industry, marking a key step in the firm's push into a market the company values at $23 billion. The contract, awarded by a United Arab Emirates-based investment group, is part of a multi-stage development program for a fragrance raw material described as among the most valuable in the world, with premium grades fetching tens of thousands of dollars per kilogram.
Will BioHarvest Sciences Inc. (BHST) Report Negative Earnings Next Week? What You Should Know
BioHarvest Sciences Inc. (BHST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioHarvest Sciences names co-founder Rakib as CEO in leadership transition
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Wednesday it has appointed co-founder Dr Zaki Rakib as CEO, consolidating leadership of its research, manufacturing, and operations under a unified structure as the botanical technology company sharpens its growth strategy. Rakib, who previously served as executive chairman, will take charge of the company's contract development and manufacturing organization (CDMO) division.
BioHarvest Sciences Inc. (BHST) Reports Q4 Loss, Lags Revenue Estimates
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.17 per share a year ago.
BioHarvest Sciences achieves revenue gains and margin expansion, narrows losses in 2025
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) has reported its financial results for the fourth quarter and full year 2025, highlighting revenue growth, improved margins, and continued investment in its product and contract manufacturing businesses. The company recorded full-year revenue of $34.5 million, representing a 37% increase compared to 2024.
BioHarvest Sciences advances sustainable fragrance production with rare plant breakthrough
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has completed the first stage of a multi-phase development program focused on a rare scent-producing plant used in the global fragrance industry. The work was carried out through the company's contract development and manufacturing organization (CDMO) division under an agreement signed about a year ago.
